- ¥931
- BD
- 美国
- 554724
- 2025年12月16日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 英文名：
Protein Transport Inhibitor (Containing Monensin)
- 库存：
10
- 供应商：
研卉生物
- 规格：
0.7ml
Brand BD GolgiStop™ Contents Monensin solution Application Intracellular staining (flow cytometry) (Routinely Tested)
Regulatory Status RUO
Description
The ex vivo addition of BD GolgiStop™, a protein transport inhibitor containing monensin, to in vitro- or in vivo-stimulated lymphoid cells blocks their intracellular protein transport processes. This results in the accumulation of cytokines and/or proteins in the Golgi complex. The increased accumulation of cytokines in the cell enhances the detectability of cytokine-producing cells with flow cytometric analysis.
Investigators should note that the appearance of BD GolgiStop™ may range in color from clear (colorless) to a light yellow.
Suggested Companion Products
Preparation and Storage
Product Notices
- Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
Stimulation of Cells: Various in vitro methods have been reported for stimulating cells to produce cytokines. Polyclonal activators have been particularly useful for inducing cytokine-producing cells. These activators include the following: concanavalin A, lipopolysaccharide, phorbol esters plus calcium ionophore or ionomycin, phytohaemaglutinin, staphlylococcus, entertoxin B, and monoclonal antibodies directed against subunits of the TCR/CD3 complex (with or without antibodies directed against costimulatory receptors, such as CD28).
Procedure for Using BD GolgiStop™: Add 4 µl of BD GolgiStop™ for every 6 mL of cell culture (e.g., ~10^6 cells/mL) and mix thoroughly. Treatment of stimulated cells for 4 to 6 hours with BD GolgiStop™ significantly increases the ability to detect cytokine-producing cells by immunofluorescent staining. It is recommended that BD GolgiStop™ not be kept in cell culture for longer than 12 hours.
As an alternative to BD GolgiStop™, investigators may wish to use BD GolgiPlug™ , a protein transport inhibitor containing brefeldin A (Cat. No. 555029). BD GolgiStop™ and BD GolgiPlug™ have been found to have differential effects on intracellular cytokine staining that is time, activator and cytokine dependent. These factors must be considered when carrying out intracellular staining.
Danger: BD GolgiStop™ Protein Transport Inhibitor, containing monensin (component 51-2092KZ) contains 99.61% ethanol (w/w) and 0.26% monensin, mononatriumsalz (w/w).
Hazard statements:
Highly flammable liquid and vapor.
Causes serious eye irritation.
Harmful if swallowed.
Precautionary statements:
Keep away from heat/sparks/open flames/hot surfaces. No smoking.
Wear protective gloves / eye protection.
Wear protective clothing.
IF ON SKIN (or hair): Remove / Take off immediately all contaminated clothing. Rinse skin with water / shower.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
IF SWALLOWED: Call a POISON CENTRE/doctor if you feel unwell. Rinse mouth.
Dispose of contents / container in accordance with local / regional / national / international regulations.Keep container tightly closed.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验Synchronizing Protein Transport in the Secretory Pathway
?intersecting and non?intersecting pathways exist in cells to carry out proper transport, modification, and addressing. To analyze and visualize the intracellular trafficking of any secretory protein, we developed the retention using selective hooks (RUSH
α-Amylase inhibitors are heat-labile proteins that are active against salivary, pancreatic, bacterial, or insect α-amylases. Two thirds of the albumin fractions of wheat are composed of multiple protein components capable of inhibiting α
The determination of the protein content of urokinase-type plasminogen activator (uPA) and its inhibitor, PAI-1, in breast cancer tissue extracts is used clinically to identify patients at risk to experience disease recurrence (metastasis
技术资料暂无技术资料 索取技术资料
